Grifols SA (GRFS) shares rallied sharply during the intraday trading session on Wednesday, soaring 6.37% on the back of robust fourth-quarter financial results. The Spanish pharmaceutical and healthcare company reported impressive growth in its key metrics for the quarter.
The company's revenue for the quarter climbed 13.6% year-over-year on a constant currency basis, reaching €1.976 billion. A significant contributor to this growth was the strong performance of Grifols' Bioscience division, which saw increased demand for its plasma-derived therapies.
Grifols also reported a 19% year-over-year increase in its adjusted EBITDA, which stood at €526 million for the fourth quarter. This impressive growth in profitability can be attributed to the company's operational efficiency and cost control measures, as well as the robust top-line performance.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。